Yesterday, Guangzhou held an epidemic prevention and control news briefing, Zhong Nanshan introduced the vaccine research and development of the situation. Pointed out that there is no strong intervention in the new crown pneumonia is unlikely to disappear; Hubei multi-initiative to help enterprises to resume production, industrial enterprises above designated size resumed work rate of 49.3%. According to reports, Hubei Province is currently adopting a differentiated strategy, zoning and grading, classification and time, conditional resumption of work and production, and the implementation of dynamic management of enterprises. Enterprises on the negative list or in the restricted category are, in principle, not allowed to resume work and production before the epidemic is lifted. National Health Commission high-level expert group leader, academician Zhong Nanshan of the Chinese Academy of Engineering yesterday in Guangzhou held an epidemic prevention and control news briefing, said the development of the new Crown pneumonia vaccine needs to be the countries of information sharing. Yesterday, Guangzhou held an epidemic prevention and control news briefing. Zhong Nanshan, head of the high-level expert group of the National Health Commission and academician of the Chinese Academy of Engineering, said at the meeting that he believes that the source and the place of the epidemic are not the same thing. The fact that the new Crown pneumonia outbreak occurred in Wuhan does not mean that the source is in Wuhan. The fact that the outbreak occurred in China does not necessarily mean the source is in China. “This is a scientific question. It’s irresponsible to jump to conclusions until you figure it out.” Talking about epidemic prevention and control All countries should take action At the conference, Zhong Nanshan said that infectious diseases have no borders and all countries should take action. Zhong Nanshan introduced, China is used to encircle the high epidemic areas, other areas of group prevention and control and other strong measures, early protection, early detection, early diagnosis, early isolation. Strong prevention and control measures are applicable to other countries? Zhong Nanshan said that in principle it can, and many countries are doing so, but not to the same extent. At the same time, he said, it is not that China’s approach is the best, according to the different characteristics of each country to consider. Zhong Nanshan preached that the first wave of the epidemic has just begun in Europe, which is highly contagious. “My view is to adopt a more active approach, not a symptomatic patient to care for him. Symptomatic patients’ families, his contacts, all go to check check, once found to isolate, in this way I think will be able to control the epidemic more quickly.” Zhong Nanshan emphasized that without any strong intervention, the new crown pneumonia will not go away. “Strong intervention must be done, all serious, acute infectious diseases must be done, can not be left to chance.” Talk about imported cases Do not look at the symptoms to do the examination Zhong Nanshan said that many of the new confirmed cases of new crown pneumonia in China are now imported cases, and are in the first wave of foreign imported cases period. Zhong Nanshan said, imported cases of infectiousness is very strong, can not relax at all. To be highly vigilant imported cases, the first wave of imported patients in high-prevalence countries, do not look at the symptoms, but to do the examination. Zhong Nanshan, new coronavirus pneumonia patients in the asymptomatic period will also spread the virus, the current new coronavirus pneumonia patients in many countries in the initial asymptomatic. Zhong Nanshan suggested that the imported cases should still be tested with nucleic acid, which is more accurate than the examination of nasal swabs and pharyngeal swabs. Talk about drug treatment next week will publish a summary of the use of chloroquine Zhong Nanshan introduced, at present, it seems that the new crown pneumonia is mainly transmitted through the respiratory tract, but is not limited to respiratory transmission, contagious than SARS, MERS are higher than the mortality rate than the influenza, although there are a number of international attempts to try a new drug, but at present there is no emergence of specific targeted new coronavirus pneumonia treatment drugs. Zhong Nanshan revealed that trials are underway to treat neocoronavirus pneumonia with chloroquine, and a summary of chloroquine use will be published next week. “So far, it looks like the average turnaround of chloroquine on the virus is about four days, which is faster than general drugs. But there are further summaries to be done.” “In the meantime, we are also conducting trials on raltegravir. In addition, traditional Chinese medicine is effective in reducing symptoms and accelerating recovery, and the results in the laboratory have been published, and the clinical effects are currently being summarized.” Zhong Nanshan said that in general, although there is no specific method, but there are already some methods to speed up the recovery of the disease and prevent the development of critical illness. Talk about vaccine development China’s vaccine has passed animal experiments For some people put forward the collective immunization argument, Zhong Nanshan said, the prevention of neocoronavirus pneumonia can not rely on collective immunity, because now there is no evidence to prove that people infected with a neocoronavirus once can be lifelong immunity, and the rapid production of an effective vaccine is a very important task at present. When introduced to China on the development of new coronavirus pneumonia vaccine progress, Zhong Nanshan said, effectiveness and safety of animal experiments have been passed, will soon be used for human clinical trials. In addition, he mentioned that Guangdong is currently developing a nucleic acid vaccine, “is doing animal experiments, but also adenovirus as the carrier of the vaccine, is working day and night, and I hope that in two or three months’ time there will be big progress.” “It is said that the U.S. will be able to use the vaccine on people in September, and China is also in the race, and it is estimated that there will not be much difference between before and after.” Zhong Nanshan said that if one country develops the new coronavirus vaccine first, how to mass produce it is also a problem. Therefore, the development of the new coronavirus vaccine requires information sharing among countries. Source: New Beijing News